<DOC>
	<DOCNO>NCT00003147</DOCNO>
	<brief_summary>Phase I trial study effectiveness gene therapy p53 gene treat patient cancer liver surgically remove . Inserting p53 gene person 's tumor may improve body 's ability fight liver cancer .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Cancer The Liver</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety adenovirus p53 construct ( adeno-p53 ) patient hepatocellular carcinoma . II . Investigate potential effect intralesional adeno-p53 give monthly percutaneous injection patient . OUTLINE : This dose escalation , multicenter study . Patients receive adenovirus p53 construct percutaneous injection maximum two lesion day 1 . Treatment repeat every 28 day 6 course . In absence dose-limiting toxicity ( DLT ) first cohort 6 patient treat , subsequent cohort 6 patient receive escalating dos drug schedule . If DLT occur 2 6 patient give dose level , dose escalation cease dose declare maximum tolerated dose . Study treatment may continue absence disease progression unacceptable adverse event .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable hepatocellular carcinoma ( HCC ) highly suspicious HCC base CT scan elevate alfafetoprotein Measurable disease abdominal CT scan Accessible ( peripheral ) lesions No metastatic disease PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 12 week Platelet count least 60,000/mm3 Absolute neutrophil count great 1,500/mm3 Prothrombin time great 16 second administration fresh frozen plasma Bilirubin great 3.0 mg/dL Creatinine le 1.5 mg/dL Child 's class A B cirrhosis eligible No uncontrolled infection Not pregnant breast feed No unstable severe intercurrent medical condition PRIOR CONCURRENT THERAPY : At least 4 week since prior chemotherapy At least 4 week since prior radiation therapy No prior hepatic transplantation No 1 prior systemic regimen hepatocellular carcinoma allow No concurrent therapy investigational agent No prior gene therapy No prior intralesional therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2000</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>